Open Access

The influence of BCL2, BAX, and ABCB1 gene expression on prognosis of adult de novo acute myeloid leukemia with normal karyotype patients

Zlatko Pravdic
Zlatko Pravdic
, 
Nada Suvajdzic Vukovic
Nada Suvajdzic Vukovic
, 
Vladimir Gasic
Vladimir Gasic
, 
Irena Marjanovic
Irena Marjanovic
, 
Teodora Karan-Djurasevic
Teodora Karan-Djurasevic
, 
Sonja Pavlovic
Sonja Pavlovic
 and 
Natasa Tosic
Natasa Tosic
   | Apr 20, 2023
Radiology and Oncology's Cover Image
About this article
Previous Article
Next Article
Cite
Article Category: Research Article
Published Online: Apr 20, 2023
Page range: 239 - 248
Received: Jan 12, 2023
Accepted: Mar 30, 2023
DOI: https://doi.org/10.2478/raon-2023-0017
Keywords
© 2023 Zlatko Pravdic et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.

Clinical characteristics for de novo acute myeloid leukemia with normal karyotype (AML-NK) patients stratified by the level of BCL2, BAX gene expression and BAX/BCL2 ratio

Parameter BCL2 BAX BAX/BCL2
Total n=51 BCL2+ n=25 BCL2− n=26 P BAX+ n=25 BAX− n=26 P BAX/BCL2high n=25 BAX/BCL2low n=26 P
Sex
  Male (%) 26 (51) 10 (38) 16 (62) 0.165 16 (62) 10 (38) 0.095 16 (62) 10 (38) 0.095
  Female (%) 25 (49) 15 (60) 10 (40) 9 (36) 16 (64) 9 (36) 16 (64)
Age* (years) 51 (23–62) 53 (27–62) 49 (23–62) 0.137 49 (27–62) 52.5 (23–62) 0.597 48 (23–62) 54 (27–62) 0.111
WBC count* (×109/L) 22 (1–349) 7 (1–184) 22.5 (2–349) 0.159 22 (1–184) 22 (0.2–349) 0.808 29 (1–349) 6 (1–184) 0.041
HB* (g/L) 99 (66–131) 103 (82–131) 98 (66–128) 97 (66–131) 105 (78–128) 98 (66–128) 103 (82–131)
  > 80 (g/L) 45 (88) 25 (56) 20 (44) 0.023 22 (49) 23 (51) 1.000 19 (53) 26 (47)
  < 80 (g/L) 6 (12) 0 6 (100) 3 (50) 3 (50) 0 6 (100) 0.010
Plts* (×109/L) 55 (8–422) 60 (8–422) 53.5 (8–169) 0.528 55 (17–169) 54.5 (8–422) 0.497 52 (8–169) 60 (8–422) 0.685
LDH *(U/L) 321 (1–2904) 175 (153–1992) 590.5 (1–2904) 0.010 386 (153–1992) 306.5 (1–2904) 0.816 605 (1–2904) 75 (153–1992) 0.002
PB blast* (%) 14 (0–98) 15 (0–98) 11 (0–97) 0.737 11 (0–92) 16 (0–98) 0.623 11 (0–97) 15 (0–98) 0.865
BM blasts* (%) 62 (30–97) 57 (30–90) 66.5 (32–90) 0.531 63 (30–97) 61 (31–90) 0.756 70 (30–90) 57 (31–97) 0.341
CD34 (%) 0.095 0.404 0.050
  present 24 (47) 15 (63) 9 (38) 10 (42) 14 (58) 8 (33) 16 (67)
  absent 27 (53) 10 (37) 17 (363) 15 (56) 12 (44) 17 (63) 10 (37)
FAB (%) 0.006 0.239 0.002
  M0 4 (8) 4 (100) 0 1 (25) 3 (75) 0 4 (100)
  M1 5 (10) 4 (80) 1 (20) 3 (60) 2 (40) 1 (20) 4 (80)
  M2 18 (35) 10 (56) 8 (44) 7 (39) 11 (62) 6 (33) 12 (67)
  M4 17 (33) 3 (18) 14 (82) 8 (47) 9 (53) 14 (82) 3 (18)
  M5 7 (14) 4 (57) 3 (43) 6 (86) 1 (14) 4 (57) 3 (43)
CR (%) 0.404 0.264 0.577
  success 28(55) 12 (43) 16 (57) 16 (57) 12 (43) 15 (54) 13 (46)
  failure 23(45) 13 (57) 10 (43) 9 (39) 14 (61) 10 (43) 13 (57)
Resistance (%) 0.024 0.703 0.044
  yes 8 (16) 7 (88) 1 (12) 3 (38) 5 (62) 1 (13) 7 (87)
  no 43 (84) 18 (42) 25 (58) 22 (51) 21 (49) 24 (56) 19 (44)
Relapse (%) 1.000 0.047 0.137
  yes 17 (61) 7 (41) 10 (59) 7 (41) 10 (59) 7 (41) 10 (59)
  no 11 (39) 5 (45) 6 (55) 9 (82) 2 (18) 8 (73) 3 (27)
FLT3-ITD mutations (%) 0.324 1.000 0.199
  present 12 (24) 4 (33) 8 (67) 6 (50) 6(50) 8 (67) 4 (33)
  absent 39 (76) 21 (54) 18 (46) 19 (49) 20 (51) 17 (44) 22 (56)
NPM1 mutations (%) 0.237 0.144 0.144
  present 17 (33) 6 (35) 11 (65) 11 (65) 6 (35) 11 (65) 6 (35)
  absent 34 (67) 19 (56) 15 (44) 14 (41) 20 (59) 14 (41) 20 (59)

Clinical characteristics for de novo acute myeloid leukemia with normal karyotype (AML-NK) patients stratified by the level of MDR1 gene expression

Parameter Total n=51 MDR1+ n=26 MDR1− n=25 P
Sex 0.051
  Male (%) 26 (51) 17 (65) 9 (35)
  Female (%) 25 (49) 9 (36) 16 (64)
Age* (years) 51 (23–62) 53 (23–62) 49 (23–62) 0.396
WBC count* (×109/L) 22 (1–349) 7 (1–184) 26 (0–349) 0.071
Hemoglobin* (g/L) 99 (66–131) 106 (78–124) 96 (66–131) 0.191
  > 80 (g/L) 45 (88) 24 (53) 21 (47)
  < 80 (g/L) 6 (12) 1 (17) 5 (83)
Platelets* (×109/L) 55 (8–422) 42 (8–422) 69.5 (16–169) 0.129
LDH *(U/L) 321 (1–2904) 175 (1–2904) 553.5 (175–1992) 0.028
PB blast* (%) 14 (0–98) 14 (0–98) 13.5 (0–87) 0.900
BM blasts* (%) 62 (30–97) 57 (30–90) 65 (33–97) 0.565
CD34 (%) 0.025
  present 24 (47) 16 (67) 8 (33)
  absent 27 (53) 9 (33) 18 (67)
FAB (%) <0.001
  M0 4 (8) 4 (100) 0
  M1 5 (10) 5 (100) 0
  M2 18 (35) 11 (61) 7 (39)
  M4 17 (33) 3 (18) 14 (82)
  M5 7 (14) 2 (29) 5 (71)
Complete remission (%) 0.781
  success 28(55) 13 (46) 15 (54)
  failure 23(45) 12 (52) 11 (48)
Resistance (%) 1.000
  yes 8 (16) 4 (50) 4 (50)
  no 43 (84) 21 (49) 22 (51)
Relapse (%) 0.460
  yes 17 (61) 9 (53) 8 (47)
  no 11 (39) 4 (36) 7 (64)
FLT3-ITD mutations (%) 0.019
  present 12 (24) 2 (17) 10 (83)
  absent 39 (76) 23 (59) 16 (41)
NPM1 mutations (%) 0.075
  present 17 (33) 5 (29) 12 (71)
  absent 34 (67) 20 (59) 14 (41)
BCL2+ 25 (49) 20 (80) 5 (20) <0.001
BCL2− 26 (51) 5 (24) 21 (76)
BAX/BCL2high 25(49) 5 (20) 20 (80)
BAX/BCL2low 26 (51) 20 (77) 6 (23) <0.001
eISSN:
1581-3207
Language:
English
Publication timeframe:
4 times per year
Journal Subjects:
Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology, Radiology
Journal RSS Feed